Gibson Dunn Advises Atossa Therapeutics on Establishing At-the-Market Facility for Sale of up to $50 Million of Common Stock

Firm News  |  February 20, 2026

---

Gibson Dunn represented Atossa Therapeutics, Inc. on establishing an at-the-market facility for the sale of up to $50 million of shares of its common stock.

Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing innovative medicines in oncology and other areas of significant unmet need. The company’s lead product candidate, (Z)-endoxifen, is currently in development across several clinical settings. Atossa is based in Seattle, Washington.

Gibson Dunn regularly advises life sciences companies on at-the-market equity offerings and other capital markets transactions.

The Gibson Dunn team included Ryan Murr, Melanie Neary, Nicholas Linke, and Anika Gidwani.